Biological age diagnostics market forecast to hit $0.99 billion by 2030

The biological age diagnostics market is expanding as demand rises for preventive health tools, personalized longevity testing and biomarker-based assessments. The Business Research Company projects the market will grow from $0.58 billion in 2026 to $0.99 billion by 2030, led by North America and fastest growth in Asia-Pacific.

Why it matters: - Biological age diagnostics are moving from a niche wellness tool toward a broader preventive health category. - The market could help clinicians and consumers identify aging-related risks earlier, supporting personalized interventions before symptoms worsen. - Rising chronic disease burdens are increasing demand for tests that can measure biological aging, not just chronological age.

What happened: - The Business Research Company released its Biological Age Diagnostics Global Market Report 2026, covering market size, trends and a 2026-2035 forecast. - The report says the market grew from $0.5 billion in 2025 to an estimated $0.58 billion in 2026. - The report forecasts the market will reach $0.99 billion by 2030, implying a 14.2% CAGR. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report includes coverage of Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample report is available here. - The full report is available here.

The details: - Biological age diagnostics measure aging using physiological, molecular and cellular markers instead of relying only on chronological age. - The approach is designed to assess how well the body’s systems function and to detect age-related changes in health and performance. - The market’s recent growth is linked to preventive healthcare, wellness demand, genomics and molecular biology advances, awareness of lifestyle effects on aging, expanded clinical laboratory infrastructure and early adoption of biomarker-based diagnostics. - Future growth drivers include AI-powered precision medicine tools, demand for personalized longevity and healthspan optimization, direct-to-consumer health testing, multi-omics integration and higher investment in aging research and biotech innovation. - Emerging trends include AI-driven biological age prediction algorithms, multi-omics longevity platforms, commercialization of epigenetic clocks and tailored healthspan enhancement programs. - The report says the rise in age-related chronic diseases is a major demand driver, including cardiovascular disease, neurodegenerative disorders, metabolic dysfunctions, musculoskeletal degeneration and certain cancers. - CDC data cited in the release says heart disease remained the leading cause of death in the U.S. in October 2024, accounting for about one in three deaths. - The same CDC data cited 919,032 cardiovascular-related deaths in 2023, with a death occurring about every 34 seconds.

Between the lines: - The market is being shaped by two forces at once: consumer interest in longevity and clinical pressure to detect chronic disease earlier. - AI and multi-omics are turning biological age testing into a data-driven diagnostics category, not just a lifestyle product. - North America’s lead suggests the region already has the infrastructure and consumer demand to commercialize these tests first, while Asia-Pacific may be catching up fastest on adoption and investment.

What's next: - The market is expected to keep scaling through 2030 as precision medicine, direct-to-consumer testing and aging research gain traction. - Report updates in 2026 will add market attractiveness scoring, TAM analysis, company scoring matrices, forecasting dashboards, market hotspots infographics and expanded trend analysis. - The Business Research Company lists Saumya Sahay as a contact for expert discussions, with regional phone numbers and marketing@tbrc.info.

The bottom line: - Biological age diagnostics are emerging as a fast-growing segment of preventive health, with strong demand signals from chronic disease management, longevity testing and AI-enabled biomarker analysis.